undamentalytics Newsletter
Sign in

Intellia Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Intellia Therapeutics, Inc. had total assets of $842m, total liabilities of $171m and shareholders' equity of $671m. It held $155m in cash against $0 of debt: net cash of $155m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2733415957160123524227189155106
Receivables6108522436997
Total current assets2813553252896177691,217998640528528
Total assets2993763473346761,2941,5201,3011,191842857
Accounts payable5234101057152012
Deferred revenue (current)20212713236444222170
Total current liabilities313141366412612711511110479
Total debt00000000000
Total liabilities——————285251319171129
Shareholders' equity2103012782705271,0401,2361,050872671728
Net debt (negative = net cash)−273−341−59−57−160−123−524−227−189−155−106
Shares outstanding—42m45m50m66m74m87m93m102m116m140m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: FENC vs NTLAIVVD vs NTLACUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Intellia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Intellia Therapeutics, Inc.